Citigroup’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Citigroup’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,316	Closed	-$13.2K	–	5933
2023 Q4	$13.2K	Buy	1,316 +470	+56%	+$2.13K	﹤0.01%	5124
2023 Q3	$2.44K	Sell	846 -377	-31%	-$1.38K	﹤0.01%	4910
2023 Q2	$4.66K	Buy	1,223 +463	+61%	+$1.3K	﹤0.01%	5193
2023 Q1	$1.41K	Sell	760 -11	-1%	-$23	﹤0.01%	5128
2022 Q4	$1.77K	Buy	771 +53	+7%	+$162	﹤0.01%	5277
2022 Q3	$2K	Sell	718 -2,371	-77%	-$7.71K	﹤0.01%	5563
2022 Q2	$17K	Sell	3,089 -366	-11%	-$1.14K	﹤0.01%	5104
2022 Q1	$8K	Sell	3,455 -3,019	-47%	-$10.3K	﹤0.01%	5650
2021 Q4	$39K	Buy	6,474 +5,496	+562%	+$52.9K	﹤0.01%	5190
2021 Q3	$14K	Sell	978 -1,254	-56%	-$14.8K	﹤0.01%	5392
2021 Q2	$29K	Buy	2,232 +1,232	+123%	+$16.5K	﹤0.01%	5112
2021 Q1	$15K	Buy	+1,000	New	+$23.6K	﹤0.01%	5417

Citigroup's GRCL Position: Q1 2024 in Review

Citigroup sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 1,316 shares — an estimated $13.2K sold.

Citigroup first reported a position in GRCL in Q1 2021 and held it in 12 quarters. The position peaked at $39K in Q4 2021. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

Citigroup reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Citigroup sold 1,316 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $13.2K.
Citigroup first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2021 and held it in 12 quarters.
Citigroup's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $39K in Q4 2021.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Citigroup's 13F filing for Q1 2024, filed 10 May 2024.